Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014:2014:729387.
doi: 10.1155/2014/729387. Epub 2014 Aug 24.

Tumor-Induced Osteomalacia: Increased Level of FGF-23 in a Patient with a Phosphaturic Mesenchymal Tumor at the Tibia Expressing Periostin

Affiliations

Tumor-Induced Osteomalacia: Increased Level of FGF-23 in a Patient with a Phosphaturic Mesenchymal Tumor at the Tibia Expressing Periostin

Anke H Hautmann et al. Case Rep Endocrinol. 2014.

Abstract

In our case, a 45-year-old male patient had multiple fractures accompanied by hypophosphatemia. FGF-23 levels were significantly increased, and total body magnetic resonance imaging (MRI) revealed a tumor mass located at the distal tibia leading to the diagnosis of tumor-induced osteomalacia (TIO). After resection of the tumor, hypophosphatemia and the increased levels of FGF-23 normalized within a few days. Subsequent microscopic examination and immunohistochemical analysis revealed a phosphaturic mesenchymal tumor mixed connective tissue variant (PMTMCT) showing a positive expression of somatostatin receptor 2A (SSTR2A), CD68, and Periostin. Electron microscopy demonstrated a poorly differentiated mesenchymal tumor with a multifocal giant cell component and evidence of neurosecretory-granules. However, the resected margins showed no tumor-free tissue, and therefore a subsequent postoperative radiotherapy was performed. The patient is still in complete remission after 34 months. Tumor resection of PMTMCTs is the therapy of choice. Subsequent radiotherapy in case of incompletely resected tumors can be an important option to avoid recurrence or metastasis even though this occurs rarely. The prognostic value of expression of Periostin has to be evaluated more precisely in a larger series of patients with TIO.

PubMed Disclaimer

Figures

Figure 1
Figure 1
(a) MRI of the giant cell tumor at the distal tibia and (b) an ultrasound examination of the tumor.
Figure 2
Figure 2
Phosphaturic mesenchymal tumor mixed connective tissue variant. (a) Histopathology of the tumor consisting of monomorphic cells with round cell nuclei without increased mitotic activity (hematoxylin-eosin stain: HE 200x), (b) scattered multinucleated giant cells (HE 400x), and ((c)–(e)) expression of CD68, SSTR2, and POSTN in tumor tissue (immunohistochemistry).
Figure 3
Figure 3
Primary formalin fixed tumor tissue and electron microscopic images. (a) Ultrastructural features of spindle shaped stromal cells with organelle-poor cytoplasm and few dense granules (arrow). Orig. mag. × 3125. (b) The granules resemble neurosecretory granules, diameter approx. 200 nm (not typical “dense core” granules), orig. mag. × 10,000. (c) Rounded tumor cell with a nuclear indentation, scant organella, and any cell surface specialized structures. Note singular electron dense granules in cytoplasm (arrows). Orig. mag. × 4,000. (d) Ultrastructural aspect of a giant multinuclear cell displaying in the organelle-rich cytoplasm some vesicular structures with pericentric dense inclusions (arrows). Orig. mag. × 3125.

References

    1. Drezner MK. Tumor-induced osteomalacia. Reviews in Endocrine and Metabolic Disorders. 2001;2(2):175–186. - PubMed
    1. Jan de Beur SM. Tumor-induced osteomalacia. The Journal of the American Medical Association. 2005;294(10):1260–1267. - PubMed
    1. White KE, Larsson TE, Econs MJ. The roles of specific genes implicated as circulating factors involved in normal and disordered phosphate homeostasis: frizzled related protein-4, matrix extracellular phosphoglycoprotein, and fibroblast growth factor 23. Endocrine Reviews. 2006;27(3):221–241. - PubMed
    1. Kaul M, Silverberg M, DiCarlo EF, Schneider R, Bass AR, Erkan D. Tumor-induced osteomalacia. Clinical Rheumatology. 2007;26(9):1575–1579. - PubMed
    1. Rendina D, De Filippo G, Tauchmanovà L, et al. Bone turnover and the osteoprotegerin-RANKL pathway in tumor-induced osteomalacia: a longitudinal study of five cases. Calcified Tissue International. 2009;85(4):293–300. - PubMed